Numbers

The Numbers

Blue Moon is a 60%-gross-margin laundry-detergent franchise that has spent its way into two consecutive years of operating losses. Revenue ran from HK$7.0B in FY2020 to HK$8.4B in FY2025 (+4% CAGR), but selling & marketing expense ran from HK$2.0B to HK$4.5B over the same period — from 28.8% of sales to 53.1%. The franchise economics are intact (gross margin has held in a tight 58–64% band for six years); the distribution economics are not. The single metric most likely to re-rate or de-rate this stock is S&M as a percentage of revenue — if it stays in the 50%+ zone the company will keep bleeding cash, and if it normalizes toward 35% the earnings power comes back fast.

Snapshot

Blue Moon trades at HK$2.96, down 81% from its HK$15.32 first-day close in December 2020. Net cash (HK$3.60B cash + HK$0.11B fixed deposits) equals HK$0.63/share — 21% of market cap — so the entire enterprise value is around HK$13.6B against HK$8.4B of revenue (EV/Sales ≈ 1.6x).

Is the franchise still healthy?

The franchise is healthy on every dimension that depends on customers buying product (gross margin is a hair below peak), but unhealthy on every dimension that depends on management choices around spend. The balance sheet makes the self-inflicted wound survivable — Blue Moon has no debt and still has HK$3.7B of liquid cash after losing HK$1.1B operating pre-tax over two years. At current burn it can fund 2–3 more years of losses before the balance-sheet thesis breaks.

Revenue and earnings power — six-year view

Revenue has grown in a narrow HK$7.0–8.6B band since the 2020 IPO — scale is not the problem. The drama is underneath: operating margin fell from 25% to -12% in four years while gross margin barely moved. That shape says the cost of keeping and growing shelf presence online has exploded, not the cost of making product.

The expense that broke the model

From FY2020 to FY2024 Blue Moon's S&M spend more than doubled in absolute terms (HK$2.0B → HK$5.0B) while revenue only grew 22%. The incremental HK$3B of distribution and promotion spend bought almost nothing — revenue over FY2023–FY2024 was HK$7.3B → HK$8.6B. The FY2025 pullback (HK$5.0B → HK$4.5B) is the first time management has visibly held the line; revenue dipped 1.7% but losses shrank 56%.

Cash generation — the balance is what's real

The cash trajectory is blunt: HK$10.9B at IPO, HK$3.6B six years later. FY2023 was the single worst year (cash down HK$3.4B — mixing operating bleed with working-capital drains and dividend). FY2024 was deceptively positive (cash up HK$874M) on a working-capital release. FY2025 resumed the burn at HK$1.6B as losses continued and management restored a dividend.

Reported cash flow detail is limited — HKEX annual results announcements publish a condensed set — but the change-in-cash line is unambiguous: roughly two-thirds of the IPO proceeds have been consumed in five years.

Balance sheet — fortress on one side, melting ice cube on the other

Total liabilities sit at HK$1.8B — mostly trade payables and accruals, no interest-bearing debt. Equity has fallen from HK$11.7B to HK$7.5B (-36%), and accumulated profits flipped from a HK$1.7B positive balance to a HK$455M deficit in FY2025. The fortress is unambiguous but it's being spent, not grown.

Stock price — 81% drawdown since listing

Two legs down: the re-rate from bubble IPO multiples (2021), then the earnings cut as the S&M problem appeared (2022–2023). A brief 2024 bounce coincided with management signalling cost discipline; the stock has since round-tripped below HK$3 as the FY2025 results confirmed the recovery is slower than hoped.

Valuation vs its own history

Earnings multiples are not meaningful — the company is loss-making. On book and sales, Blue Moon trades near its 5-year averages, which is what you'd expect when the franchise is functional but the margin outlook is uncertain. The FY2023 trough (P/B of 1.22x, P/S of 1.73x) is what the market priced when losses were still a surprise; the current level already embeds some recovery optimism.

Peer comparison — the outlier on operating leverage

Blue Moon has the best-in-class gross margin but the worst operating margin in the peer set. The gap between 59.7% gross and -4.2% operating is roughly 64 percentage points of opex — almost exactly double what Colgate-Palmolive runs on a similar gross-margin profile (44 points). If Blue Moon's opex ran at Colgate's level of sales, FY2025 operating income would be about HK$1.3B of profit instead of HK$355M of loss. That's the size of the prize if the S&M correction sticks. (CL and CLX show distorted ROE figures because aggressive buybacks have shrunk their book equity; ignore those two rows for equity-return comparison.)

Fair value framework

Consensus analyst price targets cluster between HK$2.27 and HK$2.60, low end HK$1.61, high end HK$3.40 — effectively neutral on current price. A scenario-based view is more useful than a point estimate given earnings are negative.

At HK$2.96 the market is pricing somewhere between the bear and base scenarios. The net-cash cushion (HK$0.63/share, ~21% of market cap) makes the bear case tolerable — equity is unlikely to go to zero absent sustained multi-year burn. The bull case requires 700+ basis points of operating margin recovery, which the FY2025 loss narrowing hints at but has not delivered.

Bottom line

The numbers confirm that Blue Moon still owns a premium Chinese laundry-detergent franchise: gross margin is peer-leading, the brand commands shelf at 60% gross, and the balance sheet has zero debt and HK$3.7B of cash. The numbers contradict the popular narrative that this is a structurally broken business — the gross margin has held through the collapse, which says the problem is distribution and marketing cost, not demand or pricing. What to watch next: FY2026 interim S&M as a percent of revenue. If it prints below 48%, the turn is real and the operating-margin recovery arithmetic goes fast; if it stays at 53%+, management has not actually regained control of the cost base and the cash runway becomes the story.